Top

Published in:

01-12-2017 | Original Paper

Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men

Authors: Alex Carballo-Diéguez, Rebecca Giguere, Curtis Dolezal, Cheng-Shiun Leu, Iván C. Balán, William Brown III, Christine Rael, Barbra A. Richardson, Jeanna M. Piper, Linda-Gail Bekker, Suwat Chariyalertsak, Anupong Chitwarakorn, Pedro Gonzales, Timothy H. Holtz, Albert Liu, Kenneth H. Mayer, Carmen D. Zorrilla, Javier R. Lama, Ian McGowan, Ross D. Cranston, On Behalf of the MTN-017 Protocol Team

Published in: AIDS and Behavior | Issue 12/2017

Abstract

Oral pre-exposure prophylaxis (PrEP) can prevent HIV transmission. Yet, some may prefer not to take systemic daily medication. MTN-017 was a 3-period, phase 2 safety and acceptability study of microbicide gel applied rectally either daily or before and after receptive anal intercourse (RAI), compared to daily oral tablet. At baseline, cisgender men and transgender women who reported RAI (N = 187) rated the daily oral regimen higher in overall liking, ease of use, and likelihood of future use than the gel regimens. After trying all three, 28% liked daily oral the least. Gel did not affect sexual enjoyment (88%) or improved it (7–8%). Most partners had no reaction to gel use. Ease of gel use improved significantly between the first and the last few times of daily use. A rectal gel used before and after RAI may constitute an attractive alternative to daily tablet. Experience with product use may increase acceptability.

Young I, McDaid L. How acceptable are antiretrovirals for the prevention of sexually transmitted HIV?: a review of research on the acceptability of oral pre-exposure prophylaxis and treatment as prevention. AIDS Behav. 2014;195–216.

Chakrapani V, Newman PA, Shunmugam M, Mengle S, Varghese J, Nelson R, et al. Acceptability of HIV pre-exposure prophylaxis (PrEP) and implementation challenges among men who have sex with men in India: a qualitative investigation. AIDS Patient Care STDs. 2015;29(10):569–77.CrossRefPubMed

Crosby RA, Geter A, DiClemente RJ, Salazar LF. Acceptability of condoms, circumcision and PrEP among young black men who have sex with men: a descriptive study based on effectiveness and cost. Vaccines. 2014;2:129–37.CrossRefPubMedPubMedCentral

Galea JT, Kinsler JJ, Salazar X, Lee S-J, Giron M, Sayles JN, et al. Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int. J. STD AIDS. 2011;22:256–62. http://std.sagepub.com/content/22/5/256.abstract.

Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger CL. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDS. Mary Ann Liebert, Inc., Publishers; 2013;27:248–54. http://dx.doi.org/10.1089/apc.2012.0419.

Grov C, Whitfield THF, Rendina HJ, Ventuneac A, Parsons JT. Willingness to take PrEP and potential for risk compensation among highly sexually active gay and bisexual men. AIDS Behav. 2015;19:2234–44.CrossRefPubMedPubMedCentral

Holt M. HIV pre-exposure prophylaxis and treatment as prevention: a review of awareness and acceptability among men who have sex with men in the Asia-Pacific region and the Americas. Sex Health. 2014;166–70.

Pérez-Figueroa RE, Kapadia F, Barton SC, Eddy JA, Halkitis PN. Acceptability of prep uptake among racially/ethnically diverse young men who have sex with men: the p18 study. AIDS Educ Prev. 2015;27:112–25.CrossRefPubMedPubMedCentral

Chandhiok N, Joshi SN, Gangakhedkar R. Acceptability of oral and topical HIV chemoprophylaxis in India: Implications for at-risk women and men who have sex with men. Sex Health. 2014;171–9.

10.

Young I, Flowers P, McDaid LM. Barriers to uptake and use of pre-exposure prophylaxis (PrEP) among communities most affected by HIV in the UK: findings from a qualitative study in Scotland. BMJ Open. 2014;4:e005717.CrossRefPubMedPubMedCentral

11.

Rocha LM, Campos MJ, Brito J, Fuertes R, Rojas J, Pinto N, et al. Acceptability of PrEP among HIV negative Portuguese men who have sex with men that attended 2014 Lisbon pride fair. J Int AIDS Soc. 2014;17:19734.CrossRefPubMed

12.

Carballo-Dieguez A, Bauermeister J, Ventuneac A, Dolezal C, Mayer K. Why rectal douches may be acceptable rectal-microbicide delivery vehicles for men who have sex with men. Sex Transm Dis. 2010 [cited 2013 Sep 20];37:228–33. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=yrovftk&AN=00007435-201004000-00006.

13.

Carballo-Diéguez A, Dolezal C, Bauermeister JA, O’Brien W, Ventuneac A, Mayer K. Preference for gel over suppository as delivery vehicle for a rectal microbicide: results of a randomised, crossover acceptability trial among men who have sex with men. Sex Transm Infect. 2008;84:483–7. http://www.ncbi.nlm.nih.gov/pubmed/19028952.

14.

Galea JT, Kinsler JJ, Imrie J, Nureña CR, Sánchez J, Cunningham WE. Rectal douching and implications for rectal microbicides among populations vulnerable to HIV in South America: a qualitative study. Sex Transm Infect. 2014;90:33–5. http://www.ncbi.nlm.nih.gov/pubmed/23966338.

15.

Pines HA, Gorbach PM, Weiss RE, Hess K, Murphy R, Saunders T, et al. Acceptability of potential rectal microbicide delivery systems for HIV prevention: a randomized crossover trial. AIDS Behav. 2013;17:1002–15. http://www.ncbi.nlm.nih.gov/pubmed/23114512.

16.

Chakrapani V, Newman PA, Shunmugam M, Mengle S, Nelson R, Rubincam C, et al. “Like Holding an Umbrella Before It Rains”: acceptability of future rectal microbicides among men who have sex with men in India—a modified technology acceptance model. Qual Health Res. Sage: Los Angeles; 2017 [cited 2017 Aug 18];27:1236–48. http://journals.sagepub.com/doi/10.1177/1049732317697947.

17.

Newman PA, Cameron MP, Roungprakhon S, Tepjan S, Scarpa R. Acceptability and preferences for hypothetical rectal microbicides among a community sample of young men who have sex with men and transgender women in Thailand: a discrete choice experiment. AIDS Behav. Springer US; 2016 [cited 2017 Aug 18];20:2588–601. http://link.springer.com/10.1007/s10461-015-1258-9.

18.

Frasca T, Giguere R, Ibitoye M, Dolezal C, Febo I, Cranston RD, et al. Lessons for rectal microbicide development from an acceptability trial of a placebo gel applied prior to receptive anal intercourse. Arch Sex Behav. 2016;1–9. http://dx.doi.org/10.1007/s10508-016-0735-1.

19.

McGowan I, Cranston RD, Mayer KH, Febo I, Duffill K, Siegel A, et al. Project gel a randomized rectal microbicide safety and acceptability study in young men and transgender women. Newman PA, editor. PLoS One. Public Library of Science; 2016 [cited 2017 Aug 18];11:e0158310. http://dx.plos.org/10.1371/journal.pone.0158310.

20.

Kinsler JJ, Cunningham WE, Nureña CR, Nadjat-Haiem C, Grinsztejn B, Casapia M, et al. Using Conjoint Analysis to Measure the Acceptability of Rectal Microbicides Among Men Who Have Sex with Men in Four South American Cities. AIDS Behav. [Internet]. 2012 [cited 2013 Sep 20];16:1436–47. Available from: http://link.springer.com/article/10.1007/s10461-011-0045-5.

21.

Galea JT, Kinsler JJ, Imrie J, Nureña CR, Ruiz L, Galarza LF, et al. Preparing for rectal microbicides: sociocultural factors affecting product uptake among potential South American users. Am J Public Health. 2014;104:e113–20. http://doi.org/10.2105/AJPH.2013.301731.

22.

Carballo-Diéguez A, Giguere R, Dolezal C, Bauermeister J, Leu C-S, Valladares J, et al. Rectal-specific microbicide applicator: evaluation and comparison with a vaginal applicator used rectally. AIDS Behav. 2014;18:1734–45.CrossRefPubMedPubMedCentral

23.

Ventuneac A, Carballo-Diéguez A, McGowan I, Dennis R, Adler A, Khanukhova E, et al. Acceptability of UC781 gel as a rectal microbicide among HIV-uninfected women and men. AIDS Behav. 2010;14:618–28. http://www.ncbi.nlm.nih.gov/pubmed/19757017.

24.

Newman PA, Roungprakhon S, Tepjan S. A social ecology of rectal microbicide acceptability among young men who have sex with men and transgender women in Thailand. J Int AIDS Soc. 2013;16. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732386/.

25.

Giguere R, Dolezal C, Bauermeister JA, Frasca T, Valladares J, Febo I, et al. Influence of partner type on acceptability and likelihood of use of a rectal microbicide among young men who have sex with men in the United States and Puerto Rico. J Sex Res. 2015;1–9.

26.

Bauermeister JA, Giguere R, Leu CS, Dolezal C, Febo I, Cranston RD, et al. Patterns of a rectal microbicide placebo gel use in a preparatory stage for a Phase I trial among young men who have sex with men. AIDS Behav. Springer US; 2017 [cited 2017 Aug 18];1–9. http://link.springer.com/10.1007/s10461-017-1847-x.

27.

Cranston RD, Lama JR, Richardson BA, Carballo-Diéguez A, Kunjara Na Ayudhya RP, Liu K, et al. MTN-017: a rectal phase 2 extended safety and acceptability study of tenofovir reduced-glycerin 1% gel. Clin Infect Dis. 2016;64(5):614–20.

28.

Carballo-Diéguez A, Balán IC, Brown III W, Giguere R, Dolezal C, Leu CS, et al. High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women. PLoS One. 2017;12(7):e0181607.CrossRefPubMedPubMedCentral

29.

Carballo-Dieguez A, Stein Z, Saez H, Dolezal C, Nieves-Rosa L, Diaz F. Frequent use of lubricants for anal sex among men who have sex with men: the HIV prevention potential of a microbicidal gel. Am J Public Health. 2000 [cited 2013 Sep 20];90:1117–21. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1446289/.

30.

Pines HA, Gorbach PM, Reback CJ, Landovitz RJ, Mutchler MG, Mitsuyasu R. Commercial lubricant use among HIV-negative men who have sex with men in Los Angeles: implications for the development of rectal microbicides for HIV prevention. AIDS Care. 2014;26:1609–18.CrossRefPubMedPubMedCentral

31.

Javanbakht M, Murphy R, Gorbach P, LeBlanc M-A, Pickett J. Preference and practices relating to lubricant use during anal intercourse: implications for rectal microbicides. Sex Health. 2010;7:193–8. http://www.ncbi.nlm.nih.gov/pubmed/20465986.

32.

Baeten J, Celum C. Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis. Annu Rev Med. 2013;64:219–32.CrossRefPubMed

33.

Peinado J, Lama JR, Galea JT, Segura P, Casapia M, Ortiz A, et al. Acceptability of oral versus rectal HIV preexposure prophylaxis among men who have sex with men and transgender women in Peru. J Int Assoc Provid AIDS Care. 2013;12:278–83.CrossRefPubMed

34.

Molina J-M, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373:2237–46. http://www.ncbi.nlm.nih.gov/pubmed/26624850.

Title: Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men
Authors: Alex Carballo-Diéguez
Rebecca Giguere
Curtis Dolezal
Cheng-Shiun Leu
Iván C. Balán
William Brown III
Christine Rael
Barbra A. Richardson
Jeanna M. Piper
Linda-Gail Bekker
Suwat Chariyalertsak
Anupong Chitwarakorn
Pedro Gonzales
Timothy H. Holtz
Albert Liu
Kenneth H. Mayer
Carmen D. Zorrilla
Javier R. Lama
Ian McGowan
Ross D. Cranston
On Behalf of the MTN-017 Protocol Team
Publication date: 01-12-2017
Publisher: Springer US
Published in: AIDS and Behavior / Issue 12/2017
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-017-1969-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2017

Factors Associated with Geophagy and Knowledge About Its Harmful Effects Among Native Sub-Saharan African, Caribbean and French Guiana HIV Patients Living in Northern France

Structural Interventions in HIV Prevention: A Taxonomy and Descriptive Systematic Review

Impact of Food Insecurity on Depressive Symptoms Among HIV–HCV Co-infected People

Perceived Barriers and Facilitators to Integrating HIV Prevention and Treatment with Cross-Sex Hormone Therapy for Transgender Women in Lima, Peru

Food Insecurity is Associated with Poor HIV Outcomes Among Women in the United States

Project nGage: Results of a Randomized Controlled Trial of a Dyadic Network Support Intervention to Retain Young Black Men Who Have Sex With Men in HIV Care

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page